A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” mutant of Bcr-Abl

The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the T315I ‘gatekeeper’ mutation. Here we describe a Type-II T315I inhibitor GNF-7, based upon a 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one scaffold whic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Choi, Hwan Geun, Ren, Pingda, Adrian, Francisco, Sun, Fangxian, Lee, Hyun Soo, Wang, Xia, Ding, Qiang, Zhang, Guobao, Zhang, Yongping, Liu, Yi, Tuntland, Tove, Warmuth, Markus, Manley, Paul W., Mestan, Jürgen, Gray, Nathanael S, Sim, Taebo
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4134510/
https://ncbi.nlm.nih.gov/pubmed/20604564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jm901808w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados